ID   CSF1R_HUMAN             Reviewed;         972 AA.
AC   P07333; Q6LDW5; Q6LDY4;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   02-NOV-2010, entry version 135.
DE   RecName: Full=Macrophage colony-stimulating factor 1 receptor;
DE            Short=CSF-1-R;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene c-Fms;
DE   AltName: CD_antigen=CD115;
DE   Flags: Precursor;
GN   Name=CSF1R; Synonyms=FMS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=89239490; PubMed=2524025;
RA   Hampe A., Shamoon B.M., Gobet M., Sherr C.J., Galibert F.;
RT   "Nucleotide sequence and structural organization of the human FMS
RT   proto-oncogene.";
RL   Oncogene Res. 4:9-17(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=86175013; PubMed=2421165; DOI=10.1038/320277a0;
RA   Coussens L., van Beveren C., Smith D., Chen E., Mitchell R.L.,
RA   Isacke C.M., Verma I.M., Ullrich A.;
RT   "Structural alteration of viral homologue of receptor proto-oncogene
RT   fms at carboxyl terminus.";
RL   Nature 320:277-280(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   MEDLINE=97179223; PubMed=9027509; DOI=10.1006/geno.1996.4482;
RA   Andre C., Hampe A., Lachaume P., Martin E., Wang X.P., Manus V.,
RA   Hu W.X., Galibert F.;
RT   "Sequence analysis of two genomic regions containing the KIT and the
RT   FMS receptor tyrosine kinase genes.";
RL   Genomics 39:216-226(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RX   MEDLINE=89261741; PubMed=2524648;
RA   Visvader J., Verma I.M.;
RT   "Differential transcription of exon 1 of the human c-fms gene in
RT   placental trophoblasts and monocytes.";
RL   Mol. Cell. Biol. 9:1336-1341(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RX   MEDLINE=86281820; PubMed=3525854;
RA   Wheeler E.F., Roussel M.F., Hampe A., Walker M.H., Fried V.A.,
RA   Look A.T., Rettenmier C.W., Sherr C.J.;
RT   "The amino-terminal domain of the v-fms oncogene product includes a
RT   functional signal peptide that directs synthesis of a transforming
RT   glycoprotein in the absence of feline leukemia virus gag sequences.";
RL   J. Virol. 59:224-233(1986).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RC   TISSUE=Placenta;
RA   Flick M.B., Sapi E., Kacinski B.M.;
RT   "Expression of a novel exon in the 5' UTR of human c-fms
RT   transcripts.";
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 244-295.
RX   MEDLINE=85282599; PubMed=4028159; DOI=10.1016/0092-8674(85)90099-6;
RA   Nienhuis A.W., Bunn H.F., Turner P.H., Gopal T.V., Nash W.G.,
RA   O'Brien S.J., Sherr C.J.;
RT   "Expression of the human c-fms proto-oncogene in hematopoietic cells
RT   and its deletion in the 5q- syndrome.";
RL   Cell 42:421-428(1985).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 874-972.
RX   MEDLINE=87017034; PubMed=3532121; DOI=10.1073/pnas.83.20.7800;
RA   Browning P.J., Bunn H.F., Cline A., Shuman M., Nienhuis A.W.;
RT   "'Replacement' of COOH-terminal truncation of v-fms with c-fms
RT   sequences markedly reduces transformation potential.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7800-7804(1986).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-302 AND ASN-353, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-555; TYR-556; THR-562
RP   AND THR-567, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18187866; DOI=10.2116/analsci.24.161;
RA   Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.;
RT   "Automated phosphoproteome analysis for cultured cancer cells by two-
RT   dimensional nanoLC-MS using a calcined titania/C18 biphasic column.";
RL   Anal. Sci. 24:161-166(2008).
RN   [11]
RP   FUNCTION AS IL34 RECEPTOR.
RX   PubMed=18467591; DOI=10.1126/science.1154370;
RA   Lin H., Lee E., Hestir K., Leo C., Huang M., Bosch E., Halenbeck R.,
RA   Wu G., Zhou A., Behrens D., Hollenbaugh D., Linnemann T., Qin M.,
RA   Wong J., Chu K., Doberstein S.K., Williams L.T.;
RT   "Discovery of a cytokine and its receptor by functional screening of
RT   the extracellular proteome.";
RL   Science 320:807-811(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-699; SER-713 AND
RP   SER-716, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-32; ARG-362; SER-413; VAL-536;
RP   HIS-693; ASP-920 AND GLN-921.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Protein tyrosine-kinase transmembrane receptor for CSF1
CC       and IL34.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Interacts with INPPL1/SHIP2 and THOC5 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Expressed in bone marrow and in differentiated
CC       blood mononuclear cells.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC   -!- SIMILARITY: Contains 5 Ig-like C2-type (immunoglobulin-like)
CC       domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CSF1RID40161ch5q32.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X03663; CAA27300.1; -; mRNA.
DR   EMBL; U63963; AAB51696.1; -; Genomic_DNA.
DR   EMBL; M25786; AAA58421.1; -; mRNA.
DR   EMBL; M14002; AAA35849.1; -; Genomic_DNA.
DR   EMBL; U78096; AAB51235.1; -; Genomic_DNA.
DR   EMBL; M11067; AAA35848.1; -; Genomic_DNA.
DR   EMBL; M14193; AAA35834.1; -; mRNA.
DR   IPI; IPI00011218; -.
DR   PIR; S08123; TVHUMD.
DR   RefSeq; NP_005202.2; -.
DR   UniGene; Hs.586219; -.
DR   PDB; 2I0V; X-ray; 2.80 A; A=538-922.
DR   PDB; 2I0Y; X-ray; 1.90 A; A=538-922.
DR   PDB; 2I1M; X-ray; 1.80 A; A=538-922.
DR   PDB; 2OGV; X-ray; 2.70 A; A=543-918.
DR   PDB; 3BEA; X-ray; 2.02 A; A=538-922.
DR   PDB; 3DPK; X-ray; 1.95 A; A=538-922.
DR   PDB; 3LCD; X-ray; 2.50 A; A=538-922.
DR   PDB; 3LCO; X-ray; 3.40 A; A=550-919.
DR   PDBsum; 2I0V; -.
DR   PDBsum; 2I0Y; -.
DR   PDBsum; 2I1M; -.
DR   PDBsum; 2OGV; -.
DR   PDBsum; 3BEA; -.
DR   PDBsum; 3DPK; -.
DR   PDBsum; 3LCD; -.
DR   PDBsum; 3LCO; -.
DR   ProteinModelPortal; P07333; -.
DR   SMR; P07333; 20-498.
DR   IntAct; P07333; 3.
DR   STRING; P07333; -.
DR   PhosphoSite; P07333; -.
DR   PeptideAtlas; P07333; -.
DR   PRIDE; P07333; -.
DR   Ensembl; ENST00000286301; ENSP00000286301; ENSG00000182578.
DR   Ensembl; ENST00000394307; ENSP00000377844; ENSG00000182578.
DR   GeneID; 1436; -.
DR   KEGG; hsa:1436; -.
DR   UCSC; uc003lrl.1; human.
DR   CTD; 1436; -.
DR   GeneCards; GC05M149413; -.
DR   HGNC; HGNC:2433; CSF1R.
DR   HPA; CAB008970; -.
DR   HPA; HPA012323; -.
DR   MIM; 164770; gene.
DR   PharmGKB; PA26936; -.
DR   HOGENOM; HBG445154; -.
DR   HOVERGEN; HBG004335; -.
DR   InParanoid; P07333; -.
DR   OMA; GACTYGG; -.
DR   OrthoDB; EOG9JDKT3; -.
DR   PhylomeDB; P07333; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; avb3_integrin_pathway; Integrins in angiogenesis.
DR   Pathway_Interaction_DB; ptp1bpathway; Signaling events mediated by PTP1B.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB01268; Sunitinib.
DR   NextBio; 5867; -.
DR   ArrayExpress; P07333; -.
DR   Bgee; P07333; -.
DR   CleanEx; HS_CSF1R; -.
DR   Genevestigator; P07333; -.
DR   GermOnline; ENSG00000182578; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0043235; C:receptor complex; ISS:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019955; F:cytokine binding; ISS:BHF-UCL.
DR   GO; GO:0005011; F:macrophage colony-stimulating factor recept...; TAS:ProtInc.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:BHF-UCL.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0007275; P:multicellular organismal development; TAS:ProtInc.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kin...; IEA:InterPro.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR016243; Tyr_prot_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR020729; Tyr_prot_kinase_MCSF1_rcpt.
DR   InterPro; IPR001824; Tyr_prot_kinase_rcpt_3_CS.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 5.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   PANTHER; PTHR23256:SF237; Tyr_prot_kinase_MCSF1_rcpt; 1.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Complete proteome; Disulfide bond;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Receptor; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     19       Potential.
FT   CHAIN        20    972       Macrophage colony-stimulating factor 1
FT                                receptor.
FT                                /FTId=PRO_0000016765.
FT   TOPO_DOM     20    512       Extracellular (Potential).
FT   TRANSMEM    513    537       Helical; (Potential).
FT   TOPO_DOM    538    972       Cytoplasmic (Potential).
FT   DOMAIN       21    104       Ig-like C2-type 1.
FT   DOMAIN      107    197       Ig-like C2-type 2.
FT   DOMAIN      203    290       Ig-like C2-type 3.
FT   DOMAIN      299    399       Ig-like C2-type 4.
FT   DOMAIN      402    502       Ig-like C2-type 5.
FT   DOMAIN      582    910       Protein kinase.
FT   NP_BIND     588    596       ATP (By similarity).
FT   ACT_SITE    778    778       Proton acceptor (By similarity).
FT   BINDING     616    616       ATP (By similarity).
FT   MOD_RES     555    555       Phosphoserine.
FT   MOD_RES     556    556       Phosphotyrosine.
FT   MOD_RES     562    562       Phosphothreonine.
FT   MOD_RES     567    567       Phosphothreonine.
FT   MOD_RES     699    699       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     708    708       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     713    713       Phosphoserine.
FT   MOD_RES     716    716       Phosphoserine.
FT   MOD_RES     809    809       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   CARBOHYD     45     45       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     73     73       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    153    153       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    240    240       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    275    275       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    302    302       N-linked (GlcNAc...).
FT   CARBOHYD    335    335       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    353    353       N-linked (GlcNAc...).
FT   CARBOHYD    412    412       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    428    428       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    480    480       N-linked (GlcNAc...) (Potential).
FT   DISULFID     42     84       Potential.
FT   DISULFID    127    177       Potential.
FT   DISULFID    224    278       Potential.
FT   DISULFID    419    485       Potential.
FT   VARIANT      32     32       V -> G (in dbSNP:rs56048668).
FT                                /FTId=VAR_042038.
FT   VARIANT     245    245       A -> S (in dbSNP:rs41338945).
FT                                /FTId=VAR_061290.
FT   VARIANT     279    279       V -> M (in dbSNP:rs3829986).
FT                                /FTId=VAR_049718.
FT   VARIANT     362    362       H -> R (in dbSNP:rs10079250).
FT                                /FTId=VAR_042039.
FT   VARIANT     413    413       G -> S (in dbSNP:rs34951517).
FT                                /FTId=VAR_042040.
FT   VARIANT     536    536       L -> V (in dbSNP:rs55942044).
FT                                /FTId=VAR_042041.
FT   VARIANT     693    693       P -> H (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042042.
FT   VARIANT     920    920       E -> D (in dbSNP:rs34030164).
FT                                /FTId=VAR_042043.
FT   VARIANT     921    921       R -> Q (in dbSNP:rs56059682).
FT                                /FTId=VAR_042044.
FT   VARIANT     969    969       Y -> C (in dbSNP:rs1801271).
FT                                /FTId=VAR_011953.
FT   CONFLICT     54     54       P -> A (in Ref. 2; CAA27300).
FT   HELIX       579    581
FT   STRAND      582    590
FT   STRAND      592    604
FT   TURN        605    608
FT   STRAND      612    618
FT   HELIX       624    640
FT   STRAND      649    653
FT   STRAND      655    658
FT   STRAND      660    664
FT   HELIX       671    676
FT   HELIX       752    771
FT   HELIX       781    783
FT   STRAND      784    786
FT   HELIX       788    790
FT   STRAND      792    794
FT   HELIX       798    800
FT   STRAND      809    811
FT   HELIX       819    821
FT   HELIX       824    828
FT   HELIX       834    849
FT   HELIX       863    871
FT   HELIX       883    892
FT   HELIX       897    899
FT   HELIX       903    911
FT   HELIX       917    920
SQ   SEQUENCE   972 AA;  107984 MW;  A8D99BE237573FE8 CRC64;
     MGPGVLLLLL VATAWHGQGI PVIEPSVPEL VVKPGATVTL RCVGNGSVEW DGPPSPHWTL
     YSDGSSSILS TNNATFQNTG TYRCTEPGDP LGGSAAIHLY VKDPARPWNV LAQEVVVFED
     QDALLPCLLT DPVLEAGVSL VRVRGRPLMR HTNYSFSPWH GFTIHRAKFI QSQDYQCSAL
     MGGRKVMSIS IRLKVQKVIP GPPALTLVPA ELVRIRGEAA QIVCSASSVD VNFDVFLQHN
     NTKLAIPQQS DFHNNRYQKV LTLNLDQVDF QHAGNYSCVA SNVQGKHSTS MFFRVVESAY
     LNLSSEQNLI QEVTVGEGLN LKVMVEAYPG LQGFNWTYLG PFSDHQPEPK LANATTKDTY
     RHTFTLSLPR LKPSEAGRYS FLARNPGGWR ALTFELTLRY PPEVSVIWTF INGSGTLLCA
     ASGYPQPNVT WLQCSGHTDR CDEAQVLQVW DDPYPEVLSQ EPFHKVTVQS LLTVETLEHN
     QTYECRAHNS VGSGSWAFIP ISAGAHTHPP DEFLFTPVVV ACMSIMALLL LLLLLLLYKY
     KQKPKYQVRW KIIESYEGNS YTFIDPTQLP YNEKWEFPRN NLQFGKTLGA GAFGKVVEAT
     AFGLGKEDAV LKVAVKMLKS TAHADEKEAL MSELKIMSHL GQHENIVNLL GACTHGGPVL
     VITEYCCYGD LLNFLRRKAE AMLGPSLSPG QDPEGGVDYK NIHLEKKYVR RDSGFSSQGV
     DTYVEMRPVS TSSNDSFSEQ DLDKEDGRPL ELRDLLHFSS QVAQGMAFLA SKNCIHRDVA
     ARNVLLTNGH VAKIGDFGLA RDIMNDSNYI VKGNARLPVK WMAPESIFDC VYTVQSDVWS
     YGILLWEIFS LGLNPYPGIL VNSKFYKLVK DGYQMAQPAF APKNIYSIMQ ACWALEPTHR
     PTFQQICSFL QEQAQEDRRE RDYTNLPSSS RSGGSGSSSS ELEEESSSEH LTCCEQGDIA
     QPLLQPNNYQ FC
//
